Skip to main content

Advanced or Metastatic Melanoma R3767-ONC-22122

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • Sacramento
  • Santa Barbara

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag™ and approved for the treatment of melanoma in adults and children.

Deepti Behl
Deepti Behl
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?